Related references
Note: Only part of the references are listed.A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
Mark T. J. van Bussel et al.
BRITISH JOURNAL OF CANCER (2021)
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Alice Boileve et al.
EUROPEAN JOURNAL OF CANCER (2021)
Immunotherapies in clinical development for biliary tract cancer
Arndt Vogel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Anlotinib plus TQB2450 in patients with advanced refractory biliary tract cancer (BTC): An open-label, dose-escalating, and dose-expansion cohort of phase Ib trial
Zhou Jun et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Combining PD-1 Inhibitor with VEGF/VEGFR2 Inhibitor in Chemothera-py: Report of a Patient with End-Stage Cholangiocarcinoma and Review of Literature
Zhenjiang Ma et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2021)
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
Alessandro Rizzo et al.
CANCERS (2021)
Regomune: A phase II study of regorafenib plus avelumab in solid tumors-Results of the biliary tract cancer (BTC) cohort.
Sophie Cousin et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Hepatobiliary Cancers, Version 2.2021
Al B. Benson III et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells
Farsaneh Sadeghlar et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study
Nilofer S. Azad et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular classification of cholangiocarcinoma
Corentin Louis et al.
CURRENT OPINION IN GASTROENTEROLOGY (2020)
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Sylvie Job et al.
HEPATOLOGY (2020)
A pilot study of durvalumab/tremelimumab (durva/treme) and radiation (XRT) for metastatic biliary tract cancer (mBTC): Preliminary safety and efficacy.
Theodore S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report.
Benjamin Leon Musher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic impact of CD8+T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma
Yoh Asahi et al.
SURGERY TODAY (2020)
Pharmacological targeting of natural killer cells for cancer immunotherapy
Kiho Miyazato et al.
CANCER SCIENCE (2020)
Targeting PPAR ligands as possible approaches for metabolic reprogramming of T cells in cancer immunotherapy
Saman Bahrambeigi et al.
IMMUNOLOGY LETTERS (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
Florian Huemer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study
Archana Thakur et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
A multicenter randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01).
Vaibhav Sahai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pd-1 inhibitors plus nab-paclitaxel with S1 (AS) as first line in patients with advanced biliary tract cancer.
Miaomiao Gou et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ± tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naïve advanced biliary tract cancer (aBTC).
Do-Youn Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II study of pembrolizumab plus olaparib in the treatment of patients with advanced cholangiocarcinoma.
Aiwu Ruth He et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses
Christianne Groeneveldt et al.
TRENDS IN IMMUNOLOGY (2020)
A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia
Jason D. Lickliter et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2020)
Memory T cells: strategies for optimizing tumor immunotherapy
Qingjun Liu et al.
PROTEIN & CELL (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
A new oncolytic Vaccinia virus augments antitumor immune responses to prevent tumor recurrence and metastasis after surgery
Jahangir Ahmed et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner
Marine M. Leblond et al.
CANCER IMMUNOLOGY RESEARCH (2020)
A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab
Mark C. Korpics et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
Yubin Hu et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
Victor Cervera-Carrascon et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
Oliver Klein et al.
JAMA ONCOLOGY (2020)
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Florent Peyraud et al.
CANCERS (2020)
Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial
J. Zhou et al.
ANNALS OF ONCOLOGY (2020)
Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study
T. Liu et al.
ANNALS OF ONCOLOGY (2020)
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
Mengze Lv et al.
CELL RESEARCH (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer
Lipika Goyal et al.
CLINICAL CANCER RESEARCH (2020)
Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
Fan Xiong et al.
ONCOTARGETS AND THERAPY (2020)
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Jessica Wagner et al.
MOLECULAR THERAPY (2020)
Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate
Akhilesh Pandey et al.
NATURE COMMUNICATIONS (2020)
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni R. A. Razak et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells
Thanich Sangsuwannukul et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
Antoni Ribas et al.
NATURE COMMUNICATIONS (2020)
A Perspective on Cell Therapy and Cancer Vaccine in Biliary Tract Cancers (BTCs)
Shuting Han et al.
CANCERS (2020)
Inhibition of arginase in combination with anti-PDL1 leads to increased infiltration and activation of CD8+T cells, NK cells, and CD103+dendritic cells in mouse syngeneic tumor models
Alwin Schuller et al.
CANCER RESEARCH (2020)
A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers (BTCs): A NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study
Mark Yarchoan et al.
CANCER RESEARCH (2020)
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma
Anwaar Saeed et al.
CLINICAL COLORECTAL CANCER (2019)
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
Ying Zhu et al.
GUT (2019)
Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).
Tatsuya Ioka et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Jong Woo Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Anatomical, histomorphological and molecular classification of cholangiocarcinoma
Timothy Kendall et al.
LIVER INTERNATIONAL (2019)
Immunotherapy in hepatocellular carcinoma
Luigi Buonaguro et al.
ANNALS OF HEPATOLOGY (2019)
A phase II study of anti PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
Shukui Qin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.
Vaibhav Sahai et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma
In Ho Song et al.
CLINICAL CANCER RESEARCH (2019)
Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules
Guoying Zhou et al.
JOURNAL OF HEPATOLOGY (2019)
Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory
Anja C. Bloom et al.
ONCOIMMUNOLOGY (2019)
Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications
Hsing-Ju Wu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Michael Friedlander et al.
LANCET ONCOLOGY (2019)
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma
Apostolos Sarivalasis et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer
Changqing Xie et al.
HEPATOLOGY (2019)
Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy
Gang Shi et al.
MOLECULAR THERAPY (2019)
A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity
Hayley S. Ma et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets
Benjamin A. Weinberg et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2019)
Immunobiology of cholangiocarcinoma
Emilien Loeuillard et al.
JHEP REPORTS (2019)
A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity (vol 1, 16025, 2016)
Hongwei Tian et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
Kaichao Feng et al.
PROTEIN & CELL (2018)
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Shuguang Tan et al.
PROTEIN & CELL (2018)
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
Robert L. Ferris et al.
CANCER TREATMENT REVIEWS (2018)
IDO1 in cancer: a Gemini of immune checkpoints
Lijie Zhai et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau et al.
ONCOLOGIST (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
Hui Yang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
Matthew G. Krebs et al.
CANCER RESEARCH (2018)
A phase Ib study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) combination with axitinib in patients with metastatic mucosal melanoma
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness
Ying Xie et al.
THERANOSTICS (2018)
1140PDPhase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA
K P Papadopoulos et al.
ANNALS OF ONCOLOGY (2018)
Radiation therapy and immunotherapy-a potential combination in cancer treatment
N. Asna et al.
CURRENT ONCOLOGY (2018)
Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).
Robin Kate Kelley et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib plus checkpoint inhibitors in patients (pts) with advanced intrahepatic cholangiocarcinoma (ICC): Preliminary data and correlation with next-generation sequencing.
Jianzhen Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Yelei Guo et al.
CLINICAL CANCER RESEARCH (2018)
The Efficacy of CIK-Based Immunotherapies for Advanced Solid Tumors
Hongjin Chu et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2017)
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
Ruea-Yea Huang et al.
ONCOIMMUNOLOGY (2017)
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
Valeria Simone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Steven Lemery et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Jacqueline Fontugne et al.
ONCOTARGET (2017)
A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
Justin M. David et al.
ONCOIMMUNOLOGY (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
Emma Eriksson et al.
CLINICAL CANCER RESEARCH (2017)
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
Shigeru Yutani et al.
CANCER SCIENCE (2017)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas et al.
CELL (2017)
Next generation approaches for tumor vaccination
Anand Patel et al.
CHINESE CLINICAL ONCOLOGY (2017)
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Faiz Gani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
Megan C. Duggan et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
Hong Zheng et al.
CLINICAL CANCER RESEARCH (2016)
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors
J.C. Sachdev et al.
GYNECOLOGIC ONCOLOGY (2016)
Tremelimumab-associated tumor regression following after initial progression: two case reports
Akihiko Shimomura et al.
IMMUNOTHERAPY (2016)
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Vitor Werneck Krauss Silva et al.
CHINESE CLINICAL ONCOLOGY (2016)
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
Andrew B. Sharabi et al.
LANCET ONCOLOGY (2015)
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer
Masato Matsuyama et al.
INVESTIGATIONAL NEW DRUGS (2015)
TGF-β1 expression is associated with invasion and metastasis of intrahepatic cholangiocarcinoma
Yijie Chen et al.
BIOLOGICAL RESEARCH (2015)
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
Anna R. Kwilas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer
Atsushi Aruga et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Cancer Immunotherapy Based on Mutation-Specific CD4+T Cells in a Patient with Epithelial Cancer
Eric Tran et al.
SCIENCE (2014)
Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities
Sumera Rizvi et al.
SEMINARS IN LIVER DISEASE (2014)
MUC1: a multifaceted oncoprotein with a key role in cancer progression
Sritama Nath et al.
TRENDS IN MOLECULAR MEDICINE (2014)
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
B. Goeppert et al.
BRITISH JOURNAL OF CANCER (2013)
Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
Atsushi Aruga et al.
CLINICAL CANCER RESEARCH (2013)
A Novel Armed Oncolytic Measles Vaccine Virus for the Treatment of Cholangiocarcinoma
Sebastian Lange et al.
HUMAN GENE THERAPY (2013)
Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
Masanori Kobayashi et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma
Kyun Woo Park et al.
CANCER RESEARCH AND TREATMENT (2013)
Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
Koichi Shimizu et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2012)
Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models
Li Shen et al.
PLOS ONE (2012)
Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis
Munehiro Yoshitomi et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2012)
Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer
Miho Kaida et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Strong expression of CD133 is associated with increased cholangiocarcinoma progression
Kawin Leelawat et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Liver tumor infiltrating lymphocytes: Comparison of hepatocellular and cholangiolar carcinoma
Hans-Udo Kasper et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
H. -C. Kwon et al.
ANNALS OF ONCOLOGY (2007)
Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy
WR Jarnagin et al.
CANCER GENE THERAPY (2006)
Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-Activated T cells and dendritic cells after surgery: Report of a case
Ryota Higuchi et al.
SURGERY TODAY (2006)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas
JL Marshall et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells
ACP Diederichsen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity
H Yoshida et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2003)
Stem cells, cancer, and cancer stem cells
T Reya et al.
NATURE (2001)
Share Paper
